582 related articles for article (PubMed ID: 12077285)
1. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
2. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
4. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
5. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
6. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
7. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
8. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
9. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
[TBL] [Abstract][Full Text] [Related]
10. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
11. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
Yang S; Haluska FG
J Immunol; 2004 Apr; 172(7):4599-608. PubMed ID: 15034078
[TBL] [Abstract][Full Text] [Related]
12. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
13. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
14. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Roberts JD; Niedzwiecki D; Carson WE; Chapman PB; Gajewski TF; Ernstoff MS; Hodi FS; Shea C; Leong SP; Johnson J; Zhang D; Houghton A; Haluska FG;
J Immunother; 2006; 29(1):95-101. PubMed ID: 16365605
[TBL] [Abstract][Full Text] [Related]
16. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
17. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E
J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118
[TBL] [Abstract][Full Text] [Related]
18. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
[TBL] [Abstract][Full Text] [Related]
19. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of TCR use in response to repeated epitope-specific immunization.
MonsurrĂ² V; Nielsen MB; Perez-Diez A; Dudley ME; Wang E; Rosenberg SA; Marincola FM
J Immunol; 2001 May; 166(9):5817-25. PubMed ID: 11313426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]